Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
54.63
-0.20 (-0.36%)
Nov 21, 2024, 4:00 PM EST - Market closed
Soleno Therapeutics Employees
Soleno Therapeutics had 33 employees as of December 31, 2023. The number of employees increased by 8 or 32.00% compared to the previous year.
Employees
33
Change (1Y)
8
Growth (1Y)
32.00%
Revenue / Employee
n/a
Profits / Employee
-$3,974,667
Market Cap
2.36B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CONMED | 4,000 |
UFP Technologies | 3,093 |
Premier | 2,900 |
Alignment Healthcare | 1,536 |
LeMaitre Vascular | 630 |
Geron | 141 |
Keros Therapeutics | 136 |
IDEAYA Biosciences | 124 |
SLNO News
- 7 days ago - Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 - GlobeNewsWire
- 6 weeks ago - Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha
- 6 weeks ago - SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval - GuruFocus
- 7 weeks ago - Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc - GuruFocus
- 2 months ago - Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients - Seeking Alpha
- 3 months ago - Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - GlobeNewsWire
- 3 months ago - Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire